Yihui Pharm

Yihui Pharm is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the development of novel small molecule immunotherapies. The company's research focuses on targeting innate and adaptive immune pathways, including TLR7/8, CD40, and STING, to address unmet needs in oncology and immunology. Its lead program, YH-291, is a potent TLR7/8 agonist currently undergoing clinical evaluation for the treatment of advanced solid tumors. By integrating deep expertise in medicinal chemistry and immunology, Yihui Pharm strives to create next-generation therapies with improved efficacy and safety profiles. The company is backed by prominent healthcare investors and maintains a robust pipeline of candidates aimed at transforming the treatment landscape for cancer patients.